These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 10485465)

  • 1. A single targeted Ets2 allele restricts development of mammary tumors in transgenic mice.
    Neznanov N; Man AK; Yamamoto H; Hauser CA; Cardiff RD; Oshima RG
    Cancer Res; 1999 Sep; 59(17):4242-6. PubMed ID: 10485465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ets2-dependent microenvironmental support of mouse mammary tumors.
    Tynan JA; Wen F; Muller WJ; Oshima RG
    Oncogene; 2005 Oct; 24(46):6870-6. PubMed ID: 16007139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ets transcription factors and targets in osteogenesis.
    Raouf A; Seth A
    Oncogene; 2000 Dec; 19(55):6455-63. PubMed ID: 11175361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ets2-dependent stromal regulation of mouse mammary tumors.
    Man AK; Young LJ; Tynan JA; Lesperance J; Egeblad M; Werb Z; Hauser CA; Muller WJ; Cardiff RD; Oshima RG
    Mol Cell Biol; 2003 Dec; 23(23):8614-25. PubMed ID: 14612405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered Ets transcription factor activity in prostate tumor cells inhibits anchorage-independent growth, survival, and invasiveness.
    Foos G; Hauser CA
    Oncogene; 2000 Nov; 19(48):5507-16. PubMed ID: 11114728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Down's syndrome-like skeletal abnormalities in Ets2 transgenic mice.
    Sumarsono SH; Wilson TJ; Tymms MJ; Venter DJ; Corrick CM; Kola R; Lahoud MH; Papas TS; Seth A; Kola I
    Nature; 1996 Feb; 379(6565):534-7. PubMed ID: 8596630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ets-2 transdominant mutant abolishes anchorage-independent growth and macrophage colony-stimulating factor-stimulated invasion by BT20 breast carcinoma cells.
    Sapi E; Flick MB; Rodov S; Kacinski BM
    Cancer Res; 1998 Mar; 58(5):1027-33. PubMed ID: 9500466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mouse models in the study of the Ets family of transcription factors.
    Bartel FO; Higuchi T; Spyropoulos DD
    Oncogene; 2000 Dec; 19(55):6443-54. PubMed ID: 11175360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Wnt-1 and int-2 mammary oncogene effects on the beta-catenin pathway in immortalized mouse mammary epithelial cells are not sufficient for tumorigenesis.
    Hollmann CA; Kittrell FS; Medina D; Butel JS
    Oncogene; 2001 Nov; 20(52):7645-57. PubMed ID: 11753642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo modulation of ETS genes induced by electromagnetic fields.
    Mucci N; Ianni A; Ursini CL; Arzani D; Bhat NK; Navarra P; Romano-Spica V
    In Vivo; 2001; 15(6):489-94. PubMed ID: 11887334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ets2 transcription factor inhibits mineralization and affects target gene expression during osteoblast maturation.
    Li V; Raouf A; Kitching R; Seth A
    In Vivo; 2004; 18(5):517-24. PubMed ID: 15523888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of Stat5a delays mammary cancer progression in a mouse model.
    Ren S; Cai HR; Li M; Furth PA
    Oncogene; 2002 Jun; 21(27):4335-9. PubMed ID: 12082622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of different Wnt/beta-catenin signaling components in mammary epithelium induces transdifferentiation and the formation of pilar tumors.
    Miyoshi K; Rosner A; Nozawa M; Byrd C; Morgan F; Landesman-Bollag E; Xu X; Seldin DC; Schmidt EV; Taketo MM; Robinson GW; Cardiff RD; Hennighausen L
    Oncogene; 2002 Aug; 21(36):5548-56. PubMed ID: 12165853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell cycle basis for the onset and progression of c-Myc-induced, TGFalpha-enhanced mouse mammary gland carcinogenesis.
    Liao DJ; Natarajan G; Deming SL; Jamerson MH; Johnson M; Chepko G; Dickson RB
    Oncogene; 2000 Mar; 19(10):1307-17. PubMed ID: 10713672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional mammary gland development and oncogene-induced tumor formation are not affected by the absence of the retinoblastoma gene.
    Robinson GW; Wagner KU; Hennighausen L
    Oncogene; 2001 Oct; 20(48):7115-9. PubMed ID: 11704837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolactin gene-disruption arrests mammary gland development and retards T-antigen-induced tumor growth.
    Vomachka AJ; Pratt SL; Lockefeer JA; Horseman ND
    Oncogene; 2000 Feb; 19(8):1077-84. PubMed ID: 10713693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. WAP-TAg transgenic mice and the study of dysregulated cell survival, proliferation, and mutation during breast carcinogenesis.
    Li M; Lewis B; Capuco AV; Laucirica R; Furth PA
    Oncogene; 2000 Feb; 19(8):1010-9. PubMed ID: 10713684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transgenic mice with mammary gland targeted expression of human cortactin do not develop (pre-malignant) breast tumors: studies in MMTV-cortactin and MMTV-cortactin/-cyclin D1 bitransgenic mice.
    van Rossum AG; van Bragt MP; Schuuring-Scholtes E; van der Ploeg JC; van Krieken JH; Kluin PM; Schuuring E
    BMC Cancer; 2006 Mar; 6():58. PubMed ID: 16536875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mnt-deficient mammary glands exhibit impaired involution and tumors with characteristics of myc overexpression.
    Toyo-oka K; Bowen TJ; Hirotsune S; Li Z; Jain S; Ota S; Escoubet-Lozach L; Garcia-Bassets I; Lozach J; Rosenfeld MG; Glass CK; Eisenman R; Ren B; Hurlin P; Wynshaw-Boris A
    Cancer Res; 2006 Jun; 66(11):5565-73. PubMed ID: 16740691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequent mutations of the Trp53, Hras1 and beta-catenin (Catnb) genes in 1,3-butadiene-induced mammary adenocarcinomas in B6C3F1 mice.
    Zhuang SM; Wiseman RW; Söderkvist P
    Oncogene; 2002 Aug; 21(36):5643-8. PubMed ID: 12165863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.